Gemcitabine plus etoposide in chemonaive extensive disease small-cell lung cancer: A multi-centre phase II study

Annals of Oncology

Volumn 12, Issue 6, 2001, Pages 835-840

  Vansteenkiste, J ^a   Gatzemeier, U ^b   Manegold, C ^c   Hanauske, A ^a   Weynants, P ^d   Bosquee L ^e   Blatter, J ^f   Mansouri, K ^f   Von Pawel, J ^g  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b KRANKENHAUS GROSSHANSDORF   (Germany)

^c Thoraxklinik ^*  (Germany)

^d UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^e Citadelle Hospital   (Belgium)

^f LILLY DEUTSCHLAND GMBH   (Germany)

^g Zentral Krankenhaus   (Germany)

Author keywords

Etoposide; Extensive disease small cell lung cancer; Gemcitabine; Phase II trial; Survival analysis; Treatment outcome

Indexed keywords

ETOPOSIDE; GEMCITABINE; PLATINUM;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG ACTIVITY; DRUG EFFICACY; DRUG RESPONSE; DRUG TOXICITY; EVALUATION; FEASIBILITY STUDY; FEMALE; FEVER; HUMAN; LUNG SMALL CELL CANCER; MALE; MULTICENTER STUDY; OUTPATIENT CARE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STANDARD; STATISTICAL ANALYSIS; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; DEOXYCYTIDINE; ETOPOSIDE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0034948292     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011176116567     Document Type: Article

References (29)

1. Lung cancer
2. Significant changes in the distribution of histologic types of lung cancer. A review of 4928 cases
3. Chemotherapy of lung cancer
4. Management of small cell lung cancer: Current state of the art
5. Twice-daily compared with once-daily thoracic radiotherapy in limited small cell lung cancer treated concurrently with cisplatin and etoposide
6. Chest radiotherapy in limited stage small cell lung cancer: Facts, questions, prospects
7. Review of selected randomized trials in small cell lung cancer
8. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin
9. Carboplatin versus cisplatin in solid tumors: An analysis of the literature
10. Single-agent activity of weekly gemcitabine in advanced non-small cell lung cancer: A phase II study
11. Efficacy and safety profile of gemcitabine in non-small cell lung cancer: A phase II study
12. Activity of gemcitabine in patients with non-small cell lung cancer: A multi-centre, extended phase II study
13. Symptom control in advanced non-small cell lung cancer (NSCLC): A multicenter prospective randomized phase III study of single agent gemcitabine (GEM) versus cisplatin-vindesine (PV)
14. Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC)
15. A phase II study of oral etoposide in elderly patients with small cell lung cancer
16. Gemcitabine and etoposide in small cell lung cancer: Phase I and II trials
17. Reporting results of cancer treatment
18. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small cell lung cancer
19. A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small cell lung cancer: A phase III trial of the Southeastern Cancer Study Group
20. Dose-intensity meta-analysis of chemotherapy regimens in small cell carcinoma of the lung
21. Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada
22. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small cell lung cancer
23. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small cell lung cancer: A phase III trial of the Southeastern Cancer Study Group
24. Maintenance chemotherapy in small cell lung cancer: Long-term results of a randomized trial
25. Randomized study of CODE versus alternating CAV/EP for extensive-stage small cell lung cancer: An Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group
26. Treatment of poorprognosis extensive disease small cell lung cancer with an all-oral regimen of etoposide and cyclophosphamide - A Southwest Oncology Group clinical and pharmacokinetic study
27. Combination chemotherapy for small cell lung cancer (SCLC) using intravenous (iv) vs. oral etoposide
28. Phase I study of cisplatin, etoposide and gemcitabine in small cell lung cancer (SCLC)